Skip to main
MLYS

MLYS Stock Forecast & Price Target

MLYS Analyst Ratings

Based on 6 analyst ratings
Buy
Strong Buy 67%
Buy 17%
Hold 17%
Sell 0%
Strong Sell 0%

Bulls say

Mineralys Therapeutics has developed lorundrostat, a proprietary aldosterone synthase inhibitor, which has shown a significant placebo-adjusted blood pressure reduction exceeding 10 mmHg, a factor that is likely to attract the attention of prescribers. Comparative analysis indicates that lorundrostat possesses a robust and differentiated profile for treating uncontrolled and resistant hypertension, especially in the context of Phase 3 competitor data. Additionally, the company is positioned for near-term FDA feedback and an anticipated New Drug Application submission, further enhancing its growth potential in the biopharmaceutical market.

Bears say

Mineralys Therapeutics Inc faces significant risks that contribute to a negative outlook for its stock. Key concerns include the potential failure of its product candidate, lorundrostat, to meet peak commercial revenue estimates due to limitations in market size, penetration rates, and pricing strategies. Additionally, there is a heightened risk of financial instability stemming from the company's inability to secure necessary capital resources for operations and the ongoing challenges associated with program development and commercialization.

MLYS has been analyzed by 6 analysts, with a consensus rating of Buy. 67% of analysts recommend a Strong Buy, 17% recommend Buy, 17% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Mineralys Therapeutics Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Mineralys Therapeutics Inc (MLYS) Forecast

Analysts have given MLYS a Buy based on their latest research and market trends.

According to 6 analysts, MLYS has a Buy consensus rating as of Dec 29, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $47.33, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $47.33, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Mineralys Therapeutics Inc (MLYS)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.